Asymchem Laboratories Tianjin Co Ltd
SZSE:002821
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CN |
A
|
Asymchem Laboratories Tianjin Co Ltd
SZSE:002821
|
36.3B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
959.3B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
291.8B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
238.2B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
242.2B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
305.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151.4B USD |
Loading...
|
|
| UK |
|
GSK plc
XETRA:GS71
|
103.6B EUR |
Loading...
|
Market Distribution
| Min | -2 148% |
| 30th Percentile | 14.3% |
| Median | 23% |
| 70th Percentile | 34.6% |
| Max | 775.2% |
Other Profitability Ratios
Asymchem Laboratories Tianjin Co Ltd
Glance View
In the bustling industrial landscape of Tianjin, Asymchem Laboratories stands as a beacon of innovation and precision in the biopharmaceutical world. Founded with a vision to harmonize the intricate processes of pharmaceutical development, Asymchem has evolved into a powerhouse of Contract Development and Manufacturing Organization (CDMO) services. The company provides end-to-end solutions in the pharmaceutical sector, specializing in the synthesis and manufacturing of small molecule active pharmaceutical ingredients (APIs). Their sophisticated laboratories and state-of-the-art production facilities serve a global clientele, demanding not only high-quality standards but also a seamless integration of complex processes—from drug discovery through commercialization. Asymchem's business model thrives on the symbiosis between its technical expertise and the ever-growing demand for innovative pharmaceuticals. They offer a comprehensive suite of services including research and development, process optimization, and full-scale commercial production. The company's revenue streams are tied to its ability to win long-term contracts with major pharmaceutical companies, focusing on creating custom-tailored solutions that expedite the drug development timeline while ensuring compliance with stringent regulatory standards. By aligning their operations with the needs of the biopharmaceutical industry, Asymchem secures its positioning as a key player, propelling forward the possibilities of modern medicine while ensuring sustainable growth in the competitive pharmaceutical manufacturing sector.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Asymchem Laboratories Tianjin Co Ltd is 40.4%, which is below its 3-year median of 45.2%.
Over the last 3 years, Asymchem Laboratories Tianjin Co Ltd’s Gross Margin has decreased from 45.8% to 40.4%. During this period, it reached a low of 40.4% on Sep 30, 2025 and a high of 51.8% on Sep 30, 2023.